


- 37 -

CLAIMS

What is claimed is:

1. A compound represented by



5 or a pharmaceutically acceptable salt and/or stereoisomer thereof, wherein

R^1 is independently selected from the group consisting of H, $-C_1-C_6$ alkyl, $-C(O)-C_1-C_6$ alkyl, $-C(O)-O-C_1-C_6$ alkyl, and $-S(O)_w-C_1-C_6$ alkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

q is 0, 1, 2, or 3;

10 w is 0, 1 or 2;

R^6 , if present, is independently, for each occurrence, selected from the group consisting of H, $-C_1-C_6$ alkyl, hydroxyl, and halogen, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

m is 0, 1, 2, 3, or 4;

15 R^3 is selected from the group consisting of H, $-C_1-C_6$ alkyl, $-C(O)-R^{31}$, and $-C(O)-O-R^{32}$, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

R^{31} is selected from the group consisting of H, $-C_1-C_6$ alkyl, and $-C_3-C_6$ cycloalkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each

20 independently selected from R^P , and C_3-C_6 cycloalkyl is optionally substituted by one, two or three substituents each independently selected from R^Q ;

R^{32} is selected from the group consisting of $-C_1-C_6$ alkyl, and $-C_3-C_6$ cycloalkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P , and C_3-C_6 cycloalkyl is optionally substituted by one, two or three

25 substituents each independently selected from R^Q ;

- 38 -

R^P is independently, for each occurrence, selected from the group consisting of $-C(O)NR^aR^b$, $-NR^aR^b$, hydroxyl, $-SH$, and halogen;

R^Q is independently, for each occurrence, selected from the group consisting of $-C(O)NR^aR^b$, $-NR^aR^b$, $-C_1-C_3$ alkyl, hydroxyl, and halogen; and

5 R^a and R^b are each independently, for each occurrence, selected from the group consisting of H, $-C_1-C_3$ alkyl, phenyl, and benzyl, wherein each C_1-C_3 alkyl, phenyl, and benzyl is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl, C_1-C_3 alkyl, and halogen.

2. The compound of claim 1, wherein the compound is represented by:



or a pharmaceutically acceptable salt and/or stereoisomer thereof, wherein

R^1 is independently selected from the group consisting of H, $-C_1-C_6$ alkyl, $-C(O)-C_1-C_6$ alkyl, and $-C(O)-O-C_1-C_6$ alkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

15 R^3 is selected from the group consisting of H and $-C_1-C_6$ alkyl, wherein C_1-C_6 alkyl is optionally substituted by one, two or three substituents each independently selected from R^P ;

R^P is independently, for each occurrence, selected from the group consisting of $-C(O)NR^aR^b$, $-NR^aR^b$, hydroxyl, $-SH$, and halogen; and

20 R^a and R^b are each independently, for each occurrence, selected from the group consisting of H, $-C_1-C_3$ alkyl, phenyl, and benzyl, wherein each C_1-C_3 alkyl, phenyl, and benzyl is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl, C_1-C_3 alkyl, and halogen.


3. The compound of claim 1 or 2, wherein R^1 is $-C(O)-C_1-C_4$ alkyl.

4. The compound of any one of claims 1-3, wherein R^3 is H.

25 5. The compound of any one of claims 1-3, wherein R^3 is $-C_1-C_6$ alkyl optionally substituted by one, two or three substituents independently selected from R^P .

- 39 -

6. The compound of claim 5, wherein R^3 is selected from the group consisting of:



wherein:

R^a and R^b are each independently selected for each occurrence from the group
5 consisting of H and $-C_1-C_3$ alkyl.


7. The compound of claim 6, wherein R^a and R^b are H.

8. The compound of claim 1, wherein m is 0.

9. The compound of claim 1, wherein m is 1, 2 or 3; and R^6 is F.

10. A compound selected from the group consisting of any one of Compounds AA to AH, or a
10 pharmaceutically acceptable salt and/or a stereoisomer thereof.

11. A compound represented by



or a pharmaceutically acceptable salt and/or a stereoisomer thereof.

12. A pharmaceutical composition comprising the compound of any one of claims 1-11, and a
15 pharmaceutically acceptable excipient.

13. The pharmaceutical composition of claim 12, suitable for oral administration, parenteral administration, topical administration, intravaginal administration, intrarectal administration, sublingual administration, ocular administration, transdermal administration, or nasal administration.

20 14. A method of treating of treating depression, Alzheimer's disease, attention deficit disorder, schizophrenia, or anxiety, in a patient in need thereof, comprising administering to the patient

- 40 -

an effective amount of the compound of any one of claims 1-11, or the pharmaceutical composition of claim 12 or 13.

15. A method of treating a migraine in a patient in need thereof, comprising administering to the patient an effective amount of the compound of any one of claims 1-11, or the
5 pharmaceutical composition of claim 12 or 13.

16. A method of treating neuropathic pain in a patient in need thereof, comprising administering to the patient an effective amount of the compound of any one of claims 1-11, or the pharmaceutical composition of claim 12 or 13.

17. A method of treating traumatic brain injury in a patient in need thereof, comprising
10 administering to the patient an effective amount of the compound of any one of claims 1-11, or the pharmaceutical composition of claim 12 or 13.

18. A method of treating a neurodevelopmental disorder related to synaptic dysfunction in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of any one of claims 1-11, or the pharmaceutical
15 composition of claim 12 or 13.

19. A method of treating a cognitive impairment disorder in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of any one of claims 1-11, or the pharmaceutical composition of claim 12 or 13.